Valion Bio (VBIO) Accounts Payables (2021 - 2026)
Valion Bio (VBIO) posted quarterly Accounts Payables of $264000.0 for Q4 2025, up 111.2% year-over-year from $125000.0 in Q4 2024, and down 43.23% quarter-over-quarter from $465000.0 in Q3 2025.
Valion Bio (VBIO) Accounts Payables (2021 - 2026) Analysis & Trends
Valion Bio's Accounts Payables history runs 5 years deep, the most recent figure standing at $264000.0 for Q4 2025.
- In Q4 2025, Accounts Payables rose 111.2% year-over-year to $264000.0; the TTM figure through Dec 2025 stood at $264000.0 (up 111.2% YoY), while the FY2025 annual figure was $264000.0, up 111.2% from the prior year.
- Accounts Payables for Q4 2025 stood at $264000.0, down from $465000.0 in the prior quarter.
- The five-year high for Accounts Payables was $1.9 million in Q2 2022, with the low at $125000.0 in Q4 2024.
- The 5-year median for Accounts Payables is $625000.0 (2022), against an average of $728352.9.
- The sharpest annual moves came in 2024 and 2025: Accounts Payables slumped 82.47% in 2024, then soared 111.2% in 2025.
- Valion Bio's Accounts Payables stood at $789000.0 in 2021, then soared by 67.68% to $1.3 million in 2022, then sank by 46.11% to $713000.0 in 2023, then plunged by 82.47% to $125000.0 in 2024, then jumped by 111.2% to $264000.0 in 2025.
- Business Quant data shows VBIO's Accounts Payables at $264000.0 in Q4 2025, $465000.0 in Q3 2025, and $234000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 35.57 Mn |
| 10 | Valion Bio | 405,599.63 | -1.79 Mn | -45,000.00 | 639,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 639,000.00 |
| Dec 31, 2025 | 264,000.00 |
| Sep 30, 2025 | 465,000.00 |
| Jun 30, 2025 | 234,000.00 |
| Mar 31, 2025 | 438,000.00 |
| Dec 31, 2024 | 125,000.00 |
| Sep 30, 2024 | 333,000.00 |
| Jun 30, 2024 | 446,000.00 |
| Mar 31, 2024 | 547,000.00 |
| Dec 31, 2023 | 713,000.00 |
| Sep 30, 2023 | 638,000.00 |
| Jun 30, 2023 | 831,000.00 |
| Mar 31, 2023 | 1.09 Mn |
| Dec 31, 2022 | 1.32 Mn |
| Sep 30, 2022 | 1.60 Mn |
| Jun 30, 2022 | 1.92 Mn |
| Mar 31, 2022 | 625,000.00 |
| Dec 31, 2021 | 789,000.00 |